TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Post-Approval Study to Investigate The Long Term (5-Year) Survivorship of Coflex Compared to Control Fusion Study Patients
Brief Summary: Post-Approval Clinical Study Comparing the Long Term Safety and Effectiveness of coflex vs. Fusion to Treat Lumbar Spinal Stenosis


Options:
A: Arm Label: Decompression without fusion; Type: EXPERIMENTAL; Interventions: Procedure: Decompression without fusion | Arm Label: Decompression with fusion; Type: EXPERIMENTAL; Interventions: Procedure: Decompression with fusion | Intervention Type: PROCEDURE; Name: Decompression without fusion; Assigned to Arm(s): Decompression without fusion | Intervention Type: PROCEDURE; Name: Decompression with fusion; Assigned to Arm(s): Decompression with fusion
B: Arm Label: Posterolateral Fusion w/Pedicle Screws; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Decompression, Device: Posterolateral Fusion and Implantation of Pedicle Screws | Arm Label: coflex Interlaminar Technolgy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Decompression, Device: Implantation of coflex Interlaminar Technology | Intervention Type: PROCEDURE; Name: Decompression; Assigned to Arm(s): Posterolateral Fusion w/Pedicle Screws, coflex Interlaminar Technolgy | Intervention Type: DEVICE; Name: Posterolateral Fusion and Implantation of Pedicle Screws; Assigned to Arm(s): Posterolateral Fusion w/Pedicle Screws | Intervention Type: DEVICE; Name: Implantation of coflex Interlaminar Technology; Assigned to Arm(s): coflex Interlaminar Technolgy
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Lumbar Laminectomy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Lumbar Laminectomy with Instrumented Pedicle Screw Fusion | Intervention Type: PROCEDURE; Name: Lumbar Laminectomy with Instrumented Pedicle Screw Fusion; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: Lumbar Laminectomy; Assigned to Arm(s): 1
D: Arm Label: Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Decompressive laminectomy, Other: Non-surgical treatments, Procedure: Fusion--Instrumented, Procedure: Fusion-Non-instrumented | Arm Label: Non-surgical intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: Non-surgical treatments | Intervention Type: PROCEDURE; Name: Decompressive laminectomy; Assigned to Arm(s): Surgery | Intervention Type: OTHER; Name: Non-surgical treatments; Assigned to Arm(s): Non-surgical intervention, Surgery | Intervention Type: PROCEDURE; Name: Fusion--Instrumented; Assigned to Arm(s): Surgery | Intervention Type: PROCEDURE; Name: Fusion-Non-instrumented; Assigned to Arm(s): Surgery

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIB, Multi-Dose, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo in the Treatment of Psoriatic Arthritis
Brief Summary: The purpose of this study is to determine an optimal abatacept dosing regimen for the treatment of active arthritis due to psoriatic arthritis in patients who have had a prior inadequate response to disease-modifying antirheumatic drugs, including methotrexate and tumor necrosis factor alpha-blockade compounds.


Options:
A: Arm Label: Abatacept (30/10); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Abatacept (10/10); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Abatacept (3/3); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept (10/10), Abatacept (3/3), Abatacept (30/10) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: ustekinumab 45 mg; Type: EXPERIMENTAL; Interventions: Drug: ustekinumab | Arm Label: ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: ustekinumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): ustekinumab 45 mg, ustekinumab 90 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: 80 milligrams (mg) Ixekizumab Dosing Regimen 1 (Q2W); Type: EXPERIMENTAL; Interventions: Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 | Arm Label: 80 mg Ixekizumab Dosing Regimen 2 (Q4W); Type: EXPERIMENTAL; Interventions: Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 | Arm Label: 80 mg Ixekizumab Dosing Regimen 3 (Q12W); Type: EXPERIMENTAL; Interventions: Drug: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3; Assigned to Arm(s): 80 mg Ixekizumab Dosing Regimen 2 (Q4W), 80 mg Ixekizumab Dosing Regimen 3 (Q12W), 80 milligrams (mg) Ixekizumab Dosing Regimen 1 (Q2W) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Secukinumab 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 150mg | Arm Label: Secukinumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Secukinumab 300mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Secukinumab 150mg; Assigned to Arm(s): Secukinumab 150 mg | Intervention Type: DRUG; Name: Secukinumab 300mg; Assigned to Arm(s): Secukinumab 300 mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIB, Multi-Dose, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo in the Treatment of Psoriatic Arthritis
Brief Summary: The purpose of this study is to determine an optimal abatacept dosing regimen for the treatment of active arthritis due to psoriatic arthritis in patients who have had a prior inadequate response to disease-modifying antirheumatic drugs, including methotrexate and tumor necrosis factor alpha-blockade compounds.


Options:
A: Arm Label: Abatacept (30/10); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Abatacept (10/10); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Abatacept (3/3); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept (10/10), Abatacept (3/3), Abatacept (30/10) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Biological: ABT-874 | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Biological: etanercept | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: BIOLOGICAL; Name: ABT-874; Assigned to Arm(s): A | Intervention Type: BIOLOGICAL; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): C
C: Arm Label: Adalimumab; Type: OTHER; Interventions: Drug: adalimumab | Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): Adalimumab
D: Arm Label: ustekinumab 45 mg; Type: EXPERIMENTAL; Interventions: Drug: ustekinumab | Arm Label: ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: ustekinumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: ustekinumab; Assigned to Arm(s): ustekinumab 45 mg, ustekinumab 90 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIB, Multi-Dose, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo in the Treatment of Psoriatic Arthritis
Brief Summary: The purpose of this study is to determine an optimal abatacept dosing regimen for the treatment of active arthritis due to psoriatic arthritis in patients who have had a prior inadequate response to disease-modifying antirheumatic drugs, including methotrexate and tumor necrosis factor alpha-blockade compounds.


Options:
A: Arm Label: Adalimumab; Type: OTHER; Interventions: Drug: adalimumab | Intervention Type: DRUG; Name: adalimumab; Assigned to Arm(s): Adalimumab
B: Arm Label: M1095 (Sonelokimab) 30mg; Type: EXPERIMENTAL; Interventions: Drug: M1095 (Sonelokimab) | Arm Label: M1095 (Sonelokimab) 60mg; Type: EXPERIMENTAL; Interventions: Drug: M1095 (Sonelokimab) | Arm Label: M1095 (Sonelokimab) 120mg - regimen 1; Type: EXPERIMENTAL; Interventions: Drug: M1095 (Sonelokimab) | Arm Label: M1095 (Sonelokimab) 120mg - regimen 2; Type: EXPERIMENTAL; Interventions: Drug: M1095 (Sonelokimab) | Arm Label: Placebo / M1095 (Sonelokimab) 120mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: M1095 (Sonelokimab), Drug: Placebo | Arm Label: Secukinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab | Intervention Type: DRUG; Name: M1095 (Sonelokimab); Assigned to Arm(s): M1095 (Sonelokimab) 120mg - regimen 1, M1095 (Sonelokimab) 120mg - regimen 2, M1095 (Sonelokimab) 30mg, M1095 (Sonelokimab) 60mg, Placebo / M1095 (Sonelokimab) 120mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo / M1095 (Sonelokimab) 120mg | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): Secukinumab
C: Arm Label: Abatacept (30/10); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Abatacept (10/10); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Abatacept (3/3); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept (10/10), Abatacept (3/3), Abatacept (30/10) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 30 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 100 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 300 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mirikizumab; Assigned to Arm(s): 100 mg Mirikizumab, 30 mg Mirikizumab, 300 mg Mirikizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial Comparing Tension-free Vaginal Tape (TVT) to the TVT-SECUR for the Surgical Treatment of Stress Urinary Incontinence
Brief Summary: The purpoe of this study is to compare the safety and efficacy of the tension-free vaginal tape procedure (TVT) to the TVT-SECUR procedure in the treatment of stress urinary incontinence.


Options:
A: Arm Label: Single incision mini-sling; Type: EXPERIMENTAL; Interventions: Device: Ophira | Arm Label: Transobturator sling; Type: ACTIVE_COMPARATOR; Interventions: Device: Transobturator sling | Intervention Type: DEVICE; Name: Ophira; Assigned to Arm(s): Single incision mini-sling | Intervention Type: DEVICE; Name: Transobturator sling; Assigned to Arm(s): Transobturator sling
B: Arm Label: Monarc; Type: ACTIVE_COMPARATOR; Interventions: Device: Monarc | Arm Label: Mini-arc; Type: EXPERIMENTAL; Interventions: Device: Mini-arc | Intervention Type: DEVICE; Name: Mini-arc; Assigned to Arm(s): Mini-arc | Intervention Type: DEVICE; Name: Monarc; Assigned to Arm(s): Monarc
C: Arm Label: Single-incision Mini-slings (SIMS- Ajust); Type: EXPERIMENTAL; Interventions: Procedure: sub-urethral tape (TVT-O) | Arm Label: standared med urethral sling (SMUS); Type: OTHER; Interventions: Other: stand standard mid-urethral sling (TVT-O) | Intervention Type: PROCEDURE; Name: sub-urethral tape (TVT-O); Assigned to Arm(s): Single-incision Mini-slings (SIMS- Ajust) | Intervention Type: OTHER; Name: stand standard mid-urethral sling (TVT-O); Assigned to Arm(s): standared med urethral sling (SMUS)
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: tension-free vaginal tape | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: TVT-SECUR device | Intervention Type: DEVICE; Name: tension-free vaginal tape; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: TVT-SECUR device; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Effectiveness of Two Vaccination Strategies Using GlaxoSmithKline Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents
Brief Summary: Genital infections with oncogenic human papillomaviruses (HPV) are common in both men and women. The most important disease associated with oncogenic HPV infection is cervical cancer, currently the second leading cause of cancer-related death among women globally. The current study is designed to evaluate the overall impact of HPV immunization in adolescents 12-15 years of age.


Options:
A: Arm Label: Cervarix/Engerix-B A Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Biological: Engerix-B | Arm Label: Cervarix/Engerix-B B Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Biological: Engerix-B | Arm Label: Engerix-B Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Engerix-B | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix/Engerix-B A Group, Cervarix/Engerix-B B Group | Intervention Type: BIOLOGICAL; Name: Engerix-B; Assigned to Arm(s): Cervarix/Engerix-B A Group, Cervarix/Engerix-B B Group, Engerix-B Group
B: Arm Label: Active azithromycin+placebo doxycycline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Active doxycycline+placebo azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Doxycycline | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Active azithromycin+placebo doxycycline | Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): Active doxycycline+placebo azithromycin
C: Intervention Type: PROCEDURE; Name: Home sampling (urine test) for uro-genital C.trachomatis.; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: home testing kit; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Effectiveness of Two Vaccination Strategies Using GlaxoSmithKline Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents
Brief Summary: Genital infections with oncogenic human papillomaviruses (HPV) are common in both men and women. The most important disease associated with oncogenic HPV infection is cervical cancer, currently the second leading cause of cancer-related death among women globally. The current study is designed to evaluate the overall impact of HPV immunization in adolescents 12-15 years of age.


Options:
A: Arm Label: HPV Vaccine; Type: N/A; Interventions: N/A
B: Intervention Type: BIOLOGICAL; Name: HPV-16/18 L1/AS04; Assigned to Arm(s): N/A
C: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix™ | Arm Label: Havrix Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Havrix™-based investigational formulation | Intervention Type: BIOLOGICAL; Name: Cervarix™; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Havrix™-based investigational formulation; Assigned to Arm(s): Havrix Group
D: Arm Label: Cervarix/Engerix-B A Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Biological: Engerix-B | Arm Label: Cervarix/Engerix-B B Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Biological: Engerix-B | Arm Label: Engerix-B Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Engerix-B | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix/Engerix-B A Group, Cervarix/Engerix-B B Group | Intervention Type: BIOLOGICAL; Name: Engerix-B; Assigned to Arm(s): Cervarix/Engerix-B A Group, Cervarix/Engerix-B B Group, Engerix-B Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Effectiveness of Two Vaccination Strategies Using GlaxoSmithKline Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents
Brief Summary: Genital infections with oncogenic human papillomaviruses (HPV) are common in both men and women. The most important disease associated with oncogenic HPV infection is cervical cancer, currently the second leading cause of cancer-related death among women globally. The current study is designed to evaluate the overall impact of HPV immunization in adolescents 12-15 years of age.


Options:
A: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM), Biological: Placebo | Arm Label: Gardasil Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Gardasil ® (Merck & Co. Inc), Biological: Placebo | Intervention Type: BIOLOGICAL; Name: GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM); Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Gardasil ® (Merck & Co. Inc); Assigned to Arm(s): Gardasil Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Gardasil Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Cervarix Group
B: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: HPV-16/18 vaccine (Cervarix™) | Arm Label: Aimmugen Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Aimmugen™ | Intervention Type: BIOLOGICAL; Name: HPV-16/18 vaccine (Cervarix™); Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Aimmugen™; Assigned to Arm(s): Aimmugen Group
C: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine) | Intervention Type: BIOLOGICAL; Name: GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine); Assigned to Arm(s): Cervarix Group
D: Arm Label: Cervarix/Engerix-B A Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Biological: Engerix-B | Arm Label: Cervarix/Engerix-B B Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix, Biological: Engerix-B | Arm Label: Engerix-B Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Engerix-B | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix/Engerix-B A Group, Cervarix/Engerix-B B Group | Intervention Type: BIOLOGICAL; Name: Engerix-B; Assigned to Arm(s): Cervarix/Engerix-B A Group, Cervarix/Engerix-B B Group, Engerix-B Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing Depressive Symptoms in Physically Ill Youth
Brief Summary: Children and adolescents with inflammatory bowel disease (IBD) have high rates of depressive symptoms and more trouble with daily functioning than those without physical illness. The proposed study will investigate if cognitive behavioral therapy (CBT) is better than supportive therapy (SNDT) in reducing emotional distress and improving functioning in youth ages 9-17 with Crohn's disease or Ulcerative Colitis and depression. This study will also assess the effect of CBT on IBD-related factors such as disease severity, medication adherence, and physical-health related quality of life.

Hypothesis

- Individuals who receive CBT will show more improvement than individuals who receive SNDT.


Options:
A: Arm Label: Coping Skills Training + Amitriptyline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Coping Skills Training, Drug: Amitriptyline | Arm Label: Headache Education + Amitriptyline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Headache Education, Drug: Amitriptyline | Intervention Type: BEHAVIORAL; Name: Coping Skills Training; Assigned to Arm(s): Coping Skills Training + Amitriptyline | Intervention Type: BEHAVIORAL; Name: Headache Education; Assigned to Arm(s): Headache Education + Amitriptyline | Intervention Type: DRUG; Name: Amitriptyline; Assigned to Arm(s): Coping Skills Training + Amitriptyline, Headache Education + Amitriptyline
B: Arm Label: Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy | Arm Label: Supportive Non-Directive Therapy (SNDT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supportive Non-directive Therapy (SNDT) | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): Cognitive Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: Supportive Non-directive Therapy (SNDT); Assigned to Arm(s): Supportive Non-Directive Therapy (SNDT)
C: Arm Label: Teen Online Problem Solving; Type: EXPERIMENTAL; Interventions: Behavioral: Teen Online Problem Solving | Arm Label: Internet Resources Comparison; Type: EXPERIMENTAL; Interventions: Behavioral: Teen Online Problem Solving | Intervention Type: BEHAVIORAL; Name: Teen Online Problem Solving; Assigned to Arm(s): Internet Resources Comparison, Teen Online Problem Solving
D: Arm Label: Coping Skills; Type: EXPERIMENTAL; Interventions: Behavioral: Coping Skills Training | Arm Label: Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education | Intervention Type: BEHAVIORAL; Name: Coping Skills Training; Assigned to Arm(s): Coping Skills | Intervention Type: BEHAVIORAL; Name: Education; Assigned to Arm(s): Education

Answer: B